SOCS3 and hepatocellular carcinoma: Similarly, restoration of SOCS3 by FXR agonist GW4064 is observed in hepatocellular inflammation and HCC,41, 42 indicating that FXR‐SOCS3 axis may serve as a new potential target for the prevention and treatment of HCC.